CA3207734A1 - Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases - Google Patents

Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases

Info

Publication number
CA3207734A1
CA3207734A1 CA3207734A CA3207734A CA3207734A1 CA 3207734 A1 CA3207734 A1 CA 3207734A1 CA 3207734 A CA3207734 A CA 3207734A CA 3207734 A CA3207734 A CA 3207734A CA 3207734 A1 CA3207734 A1 CA 3207734A1
Authority
CA
Canada
Prior art keywords
pterostilbene
salt
silibinin
combination
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3207734A
Other languages
English (en)
French (fr)
Inventor
Jose Maria Estrela Ariguel
Maria Elena Obrador Pla
Maria Rosario Salvador Palmer
Alegria Montoro Pastor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat de Valencia
Fundacion para la Investigacion del Hospital Universitario y Politecnico La Fe de La Comunidad Valenciana
Original Assignee
Universitat de Valencia
Fundacion para la Investigacion del Hospital Universitario y Politecnico La Fe de La Comunidad Valenciana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat de Valencia, Fundacion para la Investigacion del Hospital Universitario y Politecnico La Fe de La Comunidad Valenciana filed Critical Universitat de Valencia
Publication of CA3207734A1 publication Critical patent/CA3207734A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA3207734A 2021-01-18 2022-01-18 Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases Pending CA3207734A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382036.8A EP4029496A1 (en) 2021-01-18 2021-01-18 Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
EP21382036.8 2021-01-18
PCT/EP2022/051038 WO2022152943A1 (en) 2021-01-18 2022-01-18 Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases

Publications (1)

Publication Number Publication Date
CA3207734A1 true CA3207734A1 (en) 2022-07-21

Family

ID=74205784

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3207734A Pending CA3207734A1 (en) 2021-01-18 2022-01-18 Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases

Country Status (11)

Country Link
US (1) US20250275940A1 (enExample)
EP (2) EP4029496A1 (enExample)
JP (1) JP2024504645A (enExample)
KR (1) KR20230135110A (enExample)
CN (1) CN117202900A (enExample)
AU (1) AU2022207675A1 (enExample)
CA (1) CA3207734A1 (enExample)
ES (1) ES3029832T3 (enExample)
MX (1) MX2023008447A (enExample)
PL (1) PL4277610T3 (enExample)
WO (1) WO2022152943A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115969741B (zh) * 2023-02-21 2025-02-11 水羊化妆品制造有限公司 小花茉莉花蜡和/或小花茉莉净油组合物及应用
JP7799975B2 (ja) * 2023-03-29 2026-01-16 株式会社大阪ソーダ 皮膚バリヤ機能改善剤、及び肌状態改善剤
EP4541351A1 (en) * 2023-10-18 2025-04-23 Center for Intelligent Research in Crystal Engineering, S.L. Compounds and combination as stimulators of collagen synthesis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3926711B2 (ja) * 2002-08-30 2007-06-06 株式会社ファンケル 表皮の偏平化を予防、防止、改善する皮膚老化防止用組成物
JP2006265186A (ja) * 2005-03-24 2006-10-05 Fancl Corp シリマリン含有光老化防止剤キット
US9050284B2 (en) * 2009-02-09 2015-06-09 Sami Labs Limited Orally bioavailable stilbenoids—compositions and therapeutic applications thereof
US20110136751A1 (en) * 2009-10-06 2011-06-09 Green Molecular Use of Polyphenols in the Treatment of Cancer
FR2961814B1 (fr) * 2010-06-29 2014-09-26 Isp Investments Inc Nouveaux peptides activateurs de la sirtuine 6 et composition cosmetique ou pharmaceutiques les comprenant.
MX2014003606A (es) * 2011-09-27 2015-01-16 Univ Virginia Commonwealth Enfoque metabolico selectivo para aumentar la biodisponibilidad oral de la fenilefrina y otros bioactivos metabolicos.
WO2014112194A1 (ja) * 2013-01-21 2014-07-24 富士フイルム株式会社 油性組成物、並びにそれを含むエマルション組成物及び皮膚外用組成物
WO2014151891A1 (en) * 2013-03-14 2014-09-25 Walley Darlene Topical products
WO2014168925A1 (en) * 2013-04-08 2014-10-16 Virginia Commonwealth University Compositions to alleviate presystemic metabolism of opioids
MX394291B (es) * 2013-10-30 2025-03-24 Chromadex Inc Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.
KR20170045343A (ko) * 2014-09-04 2017-04-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 피부의 장벽 기능의 ｕｖ-유도 상실을 치료하는데 사용하기 위한 국소 프테로스틸벤 조성물
CA3021022C (en) * 2016-04-14 2024-04-23 ChromaDex Inc. Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula
BR112019003579A2 (pt) * 2016-08-22 2019-05-21 Elysium Health, Inc. Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos
CN109419634B (zh) * 2017-08-31 2023-01-31 富士胶片株式会社 水包油型乳化组合物以及皮肤外用剂
CN108478479A (zh) * 2018-04-02 2018-09-04 青岛科技大学 含有能自行提供弱酸性环境的紫檀芪复合物的眼部抗皱啫喱及其制备方法

Also Published As

Publication number Publication date
CN117202900A (zh) 2023-12-08
EP4277610C0 (en) 2025-02-26
ES3029832T3 (en) 2025-06-25
WO2022152943A1 (en) 2022-07-21
PL4277610T3 (pl) 2025-08-18
MX2023008447A (es) 2023-10-09
EP4029496A1 (en) 2022-07-20
JP2024504645A (ja) 2024-02-01
EP4277610A1 (en) 2023-11-22
AU2022207675A1 (en) 2023-08-17
EP4277610B1 (en) 2025-02-26
KR20230135110A (ko) 2023-09-22
US20250275940A1 (en) 2025-09-04

Similar Documents

Publication Publication Date Title
Tajaldini et al. Protective and anticancer effects of orange peel extract and naringin in doxorubicin treated esophageal cancer stem cell xenograft tumor mouse model
Ren et al. Resveratrol: molecular mechanisms, health benefits, and potential adverse effects
Turrini et al. Potential effects of pomegranate polyphenols in cancer prevention and therapy
McCubrey et al. Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
EP4277610B1 (en) Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
Gupta et al. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy
Chu Quarter-century explorations of bioactive polyphenols: Diverse health benefits
Kim et al. Epigenetic modifications of triterpenoid ursolic acid in activating Nrf2 and blocking cellular transformation of mouse epidermal cells
Yu et al. Paeoniflorin protects human EA. hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2/heme oxygenase-1 pathway
Kumar et al. Biochemical and molecular mechanisms of radioprotective effects of naringenin, a phytochemical from citrus fruits
US20090263367A1 (en) Composition and method for promoting internal health and external appearance
Tiwari et al. Silibinin in cancer therapy: A promising prospect
US20230025435A1 (en) Compositions and methods for increasing cellular vitality and longevity and decreasing molecular ageing
Kowsari et al. Resveratrol in cancer treatment with a focus on breast cancer
Kuang et al. Precision treatment of anthracycline-induced cardiotoxicity: an updated review
Kaur et al. Targeting Peroxisome Proliferator-Activated Receptor-β/δ, Reactive Oxygen Species and Redox Signaling with Phytocompounds for Cancer Therapy
Mukherjee et al. Bioactive flavonoid apigenin and its nanoformulations: a promising hope for diabetes and cancer
KR20210098947A (ko) 님나무 (azadirachta indica) 조성물 및 암 치료 방법
Wuputra et al. Therapeutic Potential of Resveratrol in Cancer and Neurodegenerative Disorders: A Current Review
HK40104200A (en) Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
HK40104200B (en) Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
Kim et al. Biological activities of resveratrol against cancer
Rodríguez González et al. Punica granatum L. constituents for cancer prevention, chemosensitisation and therapeutic treatment
Sehrawat et al. Scientific evidence for anticancer effects of Withania somnifera and its primary bioactive component withaferin A
Acharya et al. (2 R, 3 S, 2 ″R, 3 ″R)-Manniflavanone Protects Proliferating Skeletal Muscle Cells against Oxidative Stress and Stimulates Myotube Formation

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250108

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250108

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250108

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260108

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260108

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260115

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260115

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260219

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260219

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260219

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260219